Revenue minus cost of goods sold. Graham's ≥40% threshold identifies businesses with durable pricing power. Note: software and financial companies naturally exceed this; retailers and manufacturers rarely reach it due to their cost structures.
Operating Margin31.0%
Profit after operating costs before interest and taxes. A consistent ≥15% operating margin signals a business with real competitive advantages. Capital-intensive industries (airlines, auto, commodities) rarely hit this threshold due to their structural cost base — compare within industry for context.
Net Income Margin25.6%
Bottom-line profit as a percentage of revenue. The ≥20% target reflects Buffett's preference for highly profitable businesses. Financial engineering (buybacks, tax optimisation) can inflate this temporarily — look for consistency across multiple years rather than a single strong result.
Financial Health
D
Years to Pay Off Debt13.6 yrs
Total Debt ÷ Net Income. Lower = stronger balance sheet. Important caveat: utilities, telecoms, REITs, and infrastructure companies carry large structural debt by design — their bond-like cash flows service it comfortably at ratios that would alarm Graham. Compare within sector.
Working Capital vs Long-Term Debt-$32.2B
Working Capital minus Long-Term Debt. Negative results are common and expected in capital-return-focused businesses like Apple, Domino's, and McDonald's — where aggressive buybacks and dividends intentionally reduce book equity. This does not indicate financial distress in high-FCF businesses.
Working Capital$9.9B
Current Assets minus Current Liabilities. Negative working capital can be a deliberate efficiency strategy in businesses that collect cash before paying suppliers (retailers, fast food franchises, subscription businesses). Assess alongside free cash flow generation for full context.
Valuation
F
Margin of Safety0.0%
How far below the Graham Number the stock trades. Graham required a 33% discount as a buffer against analytical error. However, the Graham Number itself assumes 1960s-era P/E and P/B norms — for modern asset-light businesses it often understates true intrinsic value, making 0% MoS appear misleadingly bad.
Price-to-Book5.99x
Market price vs book value per share. Rarely below 1.5x for quality businesses today. Intangible assets (brand, software, patents) don't appear on the balance sheet under accounting rules, making P/B artificially high for asset-light companies like software and consumer brands.
Cash Flow
A
Free Cash Flow$3.1B
Operating cash flow minus capital expenditures. Buffett's most important metric — cash a business actually generates for its owners after maintaining and growing its asset base. Consistently positive FCF is one of the strongest indicators of a durable, well-run business regardless of accounting profits.
CapEx % of Net Income9.2%
Capital expenditure as a share of net income. Low CapEx signals a capital-light business that doesn't need heavy reinvestment to sustain earnings — Buffett's ideal. High CapEx is structurally necessary in manufacturing, airlines, telecoms, and semiconductors. For these industries, a high reading reflects the business model, not poor management.
Owner Earnings$4.2B
Net Income + Depreciation & Amortisation − Capital Expenditures. Buffett's preferred measure of a company's true annual earning power — what could theoretically be distributed to owners without impairing the business. More reliable than reported EPS because it accounts for the capital cost of maintaining the business.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Metric Explanations
What each dimension measures and where the thresholds come from.
Gross Profit Margin
Revenue minus cost of goods sold. Graham's ≥40% threshold identifies businesses with durable pricing power. Note: software and financial companies naturally exceed this; retailers and manufacturers rarely reach it due to their cost structures.
Operating Margin
Profit after operating costs before interest and taxes. A consistent ≥15% operating margin signals a business with real competitive advantages. Capital-intensive industries (airlines, auto, commodities) rarely hit this threshold due to their structural cost base — compare within industry for context.
Net Income Margin
Bottom-line profit as a percentage of revenue. The ≥20% target reflects Buffett's preference for highly profitable businesses. Financial engineering (buybacks, tax optimisation) can inflate this temporarily — look for consistency across multiple years rather than a single strong result.
Years to Pay Off Debt
Total Debt ÷ Net Income. Lower = stronger balance sheet. Important caveat: utilities, telecoms, REITs, and infrastructure companies carry large structural debt by design — their bond-like cash flows service it comfortably at ratios that would alarm Graham. Compare within sector.
Working Capital vs Long-Term Debt
Working Capital minus Long-Term Debt. Negative results are common and expected in capital-return-focused businesses like Apple, Domino's, and McDonald's — where aggressive buybacks and dividends intentionally reduce book equity. This does not indicate financial distress in high-FCF businesses.
Working Capital
Current Assets minus Current Liabilities. Negative working capital can be a deliberate efficiency strategy in businesses that collect cash before paying suppliers (retailers, fast food franchises, subscription businesses). Assess alongside free cash flow generation for full context.
Margin of Safety
How far below the Graham Number the stock trades. Graham required a 33% discount as a buffer against analytical error. However, the Graham Number itself assumes 1960s-era P/E and P/B norms — for modern asset-light businesses it often understates true intrinsic value, making 0% MoS appear misleadingly bad.
Price-to-Book
Market price vs book value per share. Rarely below 1.5x for quality businesses today. Intangible assets (brand, software, patents) don't appear on the balance sheet under accounting rules, making P/B artificially high for asset-light companies like software and consumer brands.
Free Cash Flow
Operating cash flow minus capital expenditures. Buffett's most important metric — cash a business actually generates for its owners after maintaining and growing its asset base. Consistently positive FCF is one of the strongest indicators of a durable, well-run business regardless of accounting profits.
CapEx % of Net Income
Capital expenditure as a share of net income. Low CapEx signals a capital-light business that doesn't need heavy reinvestment to sustain earnings — Buffett's ideal. High CapEx is structurally necessary in manufacturing, airlines, telecoms, and semiconductors. For these industries, a high reading reflects the business model, not poor management.
Owner Earnings
Net Income + Depreciation & Amortisation − Capital Expenditures. Buffett's preferred measure of a company's true annual earning power — what could theoretically be distributed to owners without impairing the business. More reliable than reported EPS because it accounts for the capital cost of maintaining the business.
Mr. Market is currently offering Bristol-Myers Squibb Company at $65.46.
The business passes 4 of 7 of Graham's defensive criteria — adequate but not exceptional.
At $65.46, the stock trades at a 228% premium to its Graham Number of $19.96. Graham would consider this price speculative.
There is no margin of safety at the current price. Graham would advise patience and waiting for a better entry point.
Negative NCAV — liabilities exceed current assets. Common in capital-return businesses (buybacks, debt-funded dividends) and capital-intensive industries. Not automatically a warning sign..
Conclusion: This stock is better suited for Graham's Enterprising investor — one willing to devote time and skill to security selection.
Showing Key Metrics
Income Highlights
Metric
Q2 2026
Q4 2025
Q4 2024
Gross Profit %
71.3%▲
67.2%•
N/A
Operating Margin %
31.0%▲
22.5%•
N/A
Net Income %
25.6%▲
8.7%•
N/A
Diluted EPS
1.62▲
0.53•
N/A
Balance Sheet Highlights
Metric
Q2 2026
Q4 2025
Q4 2024
Total Assets
$87.6B
$90.0B
N/A
Total Debt
$45.1B▼
$47.1B•
N/A
Working Capital
$9.9B▲
$6.0B•
N/A
Years to Pay Debt
13.58
43.37
N/A
Cash Flow Highlights
Metric
Q2 2026
Q4 2025
Q4 2024
Free Cash Flow
$3.1B▲
$1.6B•
N/A
Owner Earnings
$4.2B
$2.4B
N/A
CapEx % of Net Income
9.2%
34.0%
N/A
Income Statement
2026
2025
2024
Tax Effect Of Unusual Items
51,823
-420,049
Tax Rate For Calcs
0
0
Normalized EBITDA
4,812,000
4,487,000
Total Unusual Items
275,000
-1,608,000
Total Unusual Items Excluding Goodwill
275,000
-1,608,000
Net Income From Continuing Operation Net Minority Interest
3,317,000
1,087,000
Reconciled Depreciation
594,000
977,000
Reconciled Cost Of Revenue
3,569,000
3,946,000
EBITDA
5,087,000
2,879,000
EBIT
4,493,000
1,902,000
Net Interest Income
-407,000
-432,000
Interest Expense
407,000
432,000
Normalized Income
3,093,823
2,274,951
Net Income From Continuing And Discontinued Operation
3,317,000
1,087,000
Total Expenses
8,948,000
9,690,000
Diluted Average Shares
2,048,000
2,041,000
Basic Average Shares
2,042,000
2,036,000
Diluted EPS
0
0
Basic EPS
0
0
Diluted NI Availto Com Stockholders
3,317,000
1,087,000
Net Income Common Stockholders
3,317,000
1,087,000
Net Income
3,317,000
1,087,000
Minority Interests
1,000
1,000
Net Income Including Noncontrolling Interests
3,316,000
1,085,000
Net Income Continuous Operations
3,316,000
1,085,000
Tax Provision
770,000
384,000
Pretax Income
4,086,000
1,470,000
Other Income Expense
467,000
-909,000
Other Non Operating Income Expenses
192,000
699,000
Special Income Charges
60,000
-1,590,000
Gain On Sale Of Business
138,000
Other Special Charges
5,000
10,000
Restructuring And Mergern Acquisition
73,000
1,580,000
Gain On Sale Of Security
215,000
-18,000
Net Non Operating Interest Income Expense
-407,000
-432,000
Interest Expense Non Operating
407,000
432,000
Operating Income
4,025,000
2,813,000
Operating Expense
5,222,000
5,593,000
Depreciation Amortization Depletion Income Statement
437,000
826,000
Depreciation And Amortization In Income Statement
437,000
826,000
Amortization
437,000
826,000
Amortization Of Intangibles Income Statement
437,000
826,000
Research And Development
2,959,000
2,586,000
Selling General And Administration
1,826,000
2,181,000
Selling And Marketing Expense
Gross Profit
9,247,000
8,406,000
Cost Of Revenue
3,726,000
4,097,000
Total Revenue
12,973,000
12,503,000
Operating Revenue
12,692,000
12,226,000
Balance Sheet
2026
2025
2024
Treasury Shares Number
887,000
Preferred Shares Number
3
3
Ordinary Shares Number
2,041,735
2,035,753
Share Issued
2,041,735
2,922,753
Net Debt
34,398,000
34,902,000
Total Debt
45,053,000
47,139,000
Tangible Book Value
-17,046,000
-22,634,000
Invested Capital
65,439,000
63,584,000
Working Capital
9,920,000
5,973,000
Net Tangible Assets
-17,046,000
-22,634,000
Capital Lease Obligations
1,933,000
2,028,000
Common Stock Equity
22,319,000
18,473,000
Total Capitalization
64,412,000
61,323,000
Total Equity Gross Minority Interest
22,319,000
18,506,000
Minority Interest
0
33,000
Stockholders Equity
22,319,000
18,473,000
Other Equity Interest
1,000
Gains Losses Not Affecting Retained Earnings
-1,290,000
-1,523,000
Other Equity Adjustments
-1,290,000
40,000
Foreign Currency Translation Adjustments
-997,000
-968,000
Minimum Pension Liabilities
-566,000
-648,000
Treasury Stock
43,504,000
43,579,000
Retained Earnings
20,316,000
16,896,000
Additional Paid In Capital
46,504,000
46,387,000
Capital Stock
292,000
292,000
Common Stock
292,000
292,000
Total Liabilities Net Minority Interest
65,315,000
71,532,000
Total Non Current Liabilities Net Minority Interest
46,656,000
48,115,000
Other Non Current Liabilities
815,000
824,000
Employee Benefits
307,000
330,000
Non Current Pension And Other Postretirement Benefit Plans
307,000
330,000
Tradeand Other Payables Non Current
830,000
1,407,000
Non Current Deferred Liabilities
885,000
878,000
Non Current Deferred Revenue
142,000
169,000
Non Current Deferred Taxes Liabilities
222,000
222,000
Long Term Debt And Capital Lease Obligation
43,819,000
44,676,000
Long Term Capital Lease Obligation
1,726,000
1,826,000
Long Term Debt
42,093,000
42,850,000
Current Liabilities
18,659,000
23,417,000
Other Current Liabilities
9,705,000
13,072,000
Current Debt And Capital Lease Obligation
1,234,000
2,463,000
Current Capital Lease Obligation
207,000
202,000
Current Debt
1,027,000
2,261,000
Other Current Borrowings
1,027,000
2,261,000
Pensionand Other Post Retirement Benefit Plans Current
881,000
1,561,000
Payables And Accrued Expenses
6,839,000
6,321,000
Current Accrued Expenses
587,000
484,000
Interest Payable
587,000
484,000
Payables
6,252,000
5,837,000
Dividends Payable
1,288,000
1,283,000
Total Tax Payable
806,000
979,000
Income Tax Payable
806,000
979,000
Accounts Payable
4,158,000
3,575,000
Total Assets
87,634,000
90,038,000
Total Non Current Assets
59,055,000
60,648,000
Other Non Current Assets
2,332,000
2,201,000
Defined Pension Benefit
332,000
330,000
Non Current Deferred Assets
5,362,000
5,378,000
Non Current Deferred Taxes Assets
5,362,000
5,378,000
Investments And Advances
2,386,000
2,507,000
Investmentin Financial Assets
397,000
411,000
Held To Maturity Securities
15,000
452,000
Available For Sale Securities
397,000
396,000
320,000
Long Term Equity Investment
1,989,000
2,096,000
Goodwill And Other Intangible Assets
39,365,000
41,107,000
Other Intangible Assets
17,625,000
19,353,000
Goodwill
21,740,000
21,754,000
Net PPE
9,278,000
9,125,000
Accumulated Depreciation
-5,549,000
-5,293,000
Gross PPE
14,827,000
14,418,000
Construction In Progress
1,296,000
1,619,000
Other Properties
1,486,000
1,582,000
Machinery Furniture Equipment
3,955,000
3,790,000
Buildings And Improvements
7,933,000
7,270,000
Land And Improvements
157,000
157,000
Current Assets
28,579,000
29,390,000
Other Current Assets
1,776,000
1,502,000
Restricted Cash
0
Inventory
2,737,000
2,690,000
Receivables
12,999,000
14,525,000
Other Receivables
1,583,000
2,013,000
Taxes Receivable
2,339,000
2,920,000
Accounts Receivable
9,077,000
9,592,000
Allowance For Doubtful Accounts Receivable
-885,000
-1,778,000
Gross Accounts Receivable
9,962,000
11,370,000
Cash Cash Equivalents And Short Term Investments
11,067,000
10,673,000
Other Short Term Investments
2,345,000
464,000
Cash And Cash Equivalents
8,722,000
10,209,000
Cash Flow
2026
2025
2024
Free Cash Flow
3,088,000
1,604,000
Repayment Of Debt
-1,220,000
-10,068,000
Issuance Of Debt
-130,000
5,334,000
Capital Expenditure
-305,000
-370,000
End Cash Position
8,722,000
10,218,000
Beginning Cash Position
9,583,000
15,726,000
Effect Of Exchange Rate Changes
-10,000
5,000
Changes In Cash
-851,000
-5,513,000
Financing Cash Flow
-2,630,000
-6,029,000
Cash Flow From Continuing Financing Activities
-2,630,000
-6,029,000
Proceeds From Stock Option Exercised
7,000
-33,000
Cash Dividends Paid
-1,287,000
-1,262,000
Common Stock Dividend Paid
-1,287,000
-1,262,000
Net Issuance Payments Of Debt
-1,350,000
-4,734,000
Net Short Term Debt Issuance
-130,000
-406,000
Short Term Debt Issuance
-130,000
-406,000
Net Long Term Debt Issuance
-1,220,000
-4,328,000
Long Term Debt Payments
-1,220,000
-10,068,000
Long Term Debt Issuance
5,740,000
0
Investing Cash Flow
-1,614,000
-1,458,000
Cash Flow From Continuing Investing Activities
-1,614,000
-1,458,000
Net Investment Purchase And Sale
-1,427,000
340,000
Sale Of Investment
643,000
418,000
Purchase Of Investment
-2,070,000
-78,000
Net Business Purchase And Sale
118,000
-1,428,000
Sale Of Business
209,000
279,000
Purchase Of Business
-91,000
-1,707,000
Capital Expenditure Reported
-305,000
-370,000
Operating Cash Flow
3,393,000
1,974,000
Cash Flow From Continuing Operating Activities
3,393,000
1,974,000
Change In Working Capital
-624,000
-1,654,000
Change In Other Working Capital
1,146,000
-1,330,000
Change In Payables And Accrued Expense
-551,000
-414,000
Change In Payable
-551,000
-414,000
Change In Account Payable
-29,000
-90,000
Change In Tax Payable
-522,000
-324,000
Change In Income Tax Payable
-522,000
-324,000
Change In Inventory
-36,000
71,000
Change In Receivables
-1,183,000
19,000
Other Non Cash Items
1,000
1,716,000
Stock Based Compensation
135,000
133,000
Asset Impairment Charge
422,000
584,000
Deferred Tax
-195,000
-392,000
Deferred Income Tax
-195,000
-392,000
Depreciation Amortization Depletion
594,000
977,000
Depreciation And Amortization
594,000
977,000
Operating Gains Losses
-256,000
-475,000
Earnings Losses From Equity Investments
-114,000
-190,000
Gain Loss On Sale Of Business
-142,000
-285,000
Net Income From Continuing Operations
3,316,000
1,085,000
📊Quarterly mode — Graham Fair Value & 7 Criteria require annual data. Switch to Annual for full analysis.
Quarter vs Same Quarter Last Year
YoY strips seasonality
Revenue Growth (YoY)
Prior year: $12.3B▲ $13.0B+5.7%
Revenue growth vs same quarter last year strips seasonality. Consistent double-digit growth is a Buffett hallmark.
Gross Margin
Prior year: 72.5%▲ 71.3%-1.2pp
Buffett: consistent gross margin above 40% signals durable pricing power and competitive moat.
Operating Margin
Prior year: 32.8%▲ 31.0%-1.8pp
Graham: operating margin reflects true business economics before financing. Trend matters as much as level.
Net Margin
Prior year: 10.7%▲ 25.6%+14.9pp
Net margin can be distorted by one-time items, tax timing, or interest costs — compare to operating margin for signal quality.
Quarterly Health Checks
3 Graham/Buffett criteria that are valid and reliable on quarterly data
✅ Adequate Size
Graham required scale for resilience. Quarterly revenue × 4 gives an annualised proxy.
$13.0B/qtr (≈$51.9B ann.)
vs > $1.5B annualised revenue
❌ Financial Condition
Current assets vs current liabilities — a real-time liquidity snapshot. Valid and reliable on quarterly data.
1.53x current ratio
vs ≥ 2.0x
✅ Free Cash Flow
Buffett's most important single metric. A positive FCF quarter means the business generated real cash for owners after maintaining its asset base.
$3.1B
vs Positive
Operating Cash Flow
$3.4B
Latest quarter · Buffett's cash reality check
ROIC
4.6%
Based on latest annual operating income
Return on Invested Capital — Buffett's preferred measure for asset-light businesses. ROIC > 15% consistently signals a durable competitive advantage (moat). More meaningful than P/B for software, pharma, and consumer brand companies where most value is intangible and off-balance-sheet.
Market Cap / Net Assets
6.0x
Net Assets: $22.3B
Peers & Industry
No auto-detected peers for Drug Manufacturers - General. You can manually compare BMY against any stock using the Compare tool.
"The management of a business is its most important single factor — more important than market position, patents, or financial structure."
— Benjamin Graham
Capital Allocation & Alignment
Insider Ownership
0.10%
Low — management has little skin in the game
Return on Equity (ROE)
14.9%
Adequate — returns are moderate
Return on Assets (ROA)
3.8%
Fair — average asset utilization
Debt Trend YoY
-3.0% YoY
Debt is declining — management is deleveraging
Leadership Team
Christopher Boerner Ph.
CEO & Chairman
Age 54
Pay: $5,818,520
0.175% of net income
David Elkins
Executive VP & CFO
Age 57
Pay: $3,196,077
0.096% of net income
Top Institutional Holders
Institution
% Owned
Shares
Blackrock Inc.
8.41%
171,682,888
Vanguard Capital Management LLC
6.48%
132,320,240
State Street Corporation
4.83%
98,564,914
JPMORGAN CHASE & CO
4.53%
92,475,194
Charles Schwab Investment Management, Inc.
2.99%
61,115,373
Geode Capital Management, LLC
2.71%
55,286,174
Vanguard Portfolio Management LLC
2.26%
46,230,155
Bank of America Corporation
1.60%
32,586,981
Risk Analysis
Beta (Market Risk)
0.23
Low volatility — more stable than the market
Short Interest
2.2% of float
Low short interest — market is not heavily bearish
Debt-to-Equity
2.02x
High leverage — significant financial risk
Current Ratio
1.53x
Adequate liquidity
52-Week Price Range
Low: $42.52Current: $65.46High: $68.10
Currently at 90% of 52-week range
Bristol-Myers Squibb Company (BMY) fundamental analysis — Overall grade C based on profitability, financial health, valuation and cash flow. Graham's
Fair Value: $19.96. Margin of safety: 0%. Gross profit margin: 71.3%. Operating margin: 31.0%. Net margin: 25.6%. Market cap: $133.7B. Sector: Healthcare. Industry: Drug Manufacturers - General. Analysis powered by 360investing — free fundamental stock analysis based on Benjamin Graham and Warren Buffett
principles.
Disclaimer: 360investing is provided for informational and educational purposes only and does not constitute financial, investment, legal, or tax advice. All data is sourced from public third-party providers
and may be delayed, inaccurate, or incomplete. Past performance is not indicative of future results. Analysis, scores, and valuations are algorithmic and do not represent professional investment recommendations. Always conduct your own due
diligence and consult a qualified financial adviser before making any investment decision. Use of this tool constitutes acceptance that 360investing and its operators bear no liability for decisions made based on information presented here.